Cimicifuga heracleifolia kom. Attenuates ulcerative colitis through the PI3K/AKT/NF-κB signaling pathway
Cimicifuga heracleifolia Kom. (C. heracleifolia) has demonstrated efficacy in treating gastrointestinal disorders, including splenasthenic diarrhea. Ulcerative colitis (UC), a chronic inflammatory bowel disease, shares similarities with splenasthenic diarrhea. However, the pharmacological effects of...
Gespeichert in:
| Veröffentlicht in: | Journal of ethnopharmacology 2025-01, Vol.337 (Pt 3), p.118892, Article 118892 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Pt 3 |
| container_start_page | 118892 |
| container_title | Journal of ethnopharmacology |
| container_volume | 337 |
| creator | Wu, Xue-Yi Dong, Qin-Wei Zhang, Yong-Bo Li, Jia-Xin Zhang, Mei-Qing Zhang, De-Qin Cui, Yuan-Lu |
| description | Cimicifuga heracleifolia Kom. (C. heracleifolia) has demonstrated efficacy in treating gastrointestinal disorders, including splenasthenic diarrhea. Ulcerative colitis (UC), a chronic inflammatory bowel disease, shares similarities with splenasthenic diarrhea. However, the pharmacological effects of C. heracleifolia on UC and the underlying mechanisms remain unexplored.
The present study investigates the therapeutic potential and mechanisms of C. heracleifolia in UC.
Initially, network pharmacology analysis, encompassing ingredient screening, target prediction, protein-protein interaction (PPI) network analysis, and enrichment analysis, was employed to predict the mechanisms of C. heracleifolia. The findings were further validated using transcriptomics and functional assays in a dextran sulfate sodium (DSS)-induced UC model. Additionally, bioactive compounds were identified through surface plasmon resonance (SPR) analysis, molecular docking, and cell-based assays.
A total of 52 ingredients of C. heracleifolia were screened, and 32 key targets were identified within a PPI network comprising 285 potential therapeutic targets. Enrichment analysis indicated that the anti-UC effects of C. heracleifolia are mediated through immune response modulation and the inhibition of inflammatory signaling pathways. In vivo experiments showed that C. heracleifolia mitigated histological damage in the colon, reduced the expression of phosphorylated Akt1, nuclear factor-kappa B (NF-κB) p65, and inhibitor of Kappa B kinase α/β (IKKα/β), suppressed the content of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and enhanced the expression of tight junction proteins. Moreover, cimigenoside, caffeic acid, and methyl caffeate were identified as the bioactive constituents responsible for the UC treatment effects of C. heracleifolia.
In summary, this study is the first to demonstrate that C. heracleifolia exerts therapeutic effects on UC by enhancing the intestinal mucosal barrier and inhibiting the phosphatidylinositol 3-kinase (PI3K)/AKT/NF-κB signaling pathway. These findings offer valuable insights into the clinical application of C. heracleifolia for UC management.
[Display omitted]
•The potential mechanism of Cimicifuga heracleifolia Kom. in ulcerative colitis was firstly reported by network pharmacology-based approach.•Cimicifuga heracleifolia Kom. repaired intestinal barrier.•Cimicifuga heracleifolia Kom. reduced DSS-induced colon inflammati |
| doi_str_mv | 10.1016/j.jep.2024.118892 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3115969174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378874124011917</els_id><sourcerecordid>3115969174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c235t-71bd3b15a3d2a41ed080b6be00b62788bd52259f927622f94a16ac78165bcec33</originalsourceid><addsrcrecordid>eNp9kM9u1DAQhy0EotvCA_RS-cglWY-dxI56WlYtVK2AQzlbjjPZ9TZ_FtvZqq_GQ_BMdbWFI5eZw3y_nzQfIefAcmBQLXf5Dvc5Z7zIAZSq-RuyACV5Jksp3pIFE1JlShZwQk5D2DHGJBTsPTkRtahLWakFcWs3OOu6eWPoFr2xPbpu6p2hD9OQ01WMOM4mYqBzb9M9ugNSm4DoAo1bP82bbdpIf9yI2-Xq9n757Tr78_szDW4zmt6NG7o3cftonj6Qd53pA3583Wfk5_XV_fprdvf9y816dZdZLsqYSWha0UBpRMtNAdgyxZqqQZYml0o1bcl5WXc1lxXnXV0YqIyVCqqysWiFOCOfjr17P_2aMUQ9uGCx782I0xy0ACjrqgZZJBSOqPVTCB47vfduMP5JA9MvhvVOJ8P6xbA-Gk6Zi9f6uRmw_Zf4qzQBl0cA05MHh14H63C02DqPNup2cv-pfwYfQIxc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3115969174</pqid></control><display><type>article</type><title>Cimicifuga heracleifolia kom. Attenuates ulcerative colitis through the PI3K/AKT/NF-κB signaling pathway</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Wu, Xue-Yi ; Dong, Qin-Wei ; Zhang, Yong-Bo ; Li, Jia-Xin ; Zhang, Mei-Qing ; Zhang, De-Qin ; Cui, Yuan-Lu</creator><creatorcontrib>Wu, Xue-Yi ; Dong, Qin-Wei ; Zhang, Yong-Bo ; Li, Jia-Xin ; Zhang, Mei-Qing ; Zhang, De-Qin ; Cui, Yuan-Lu</creatorcontrib><description>Cimicifuga heracleifolia Kom. (C. heracleifolia) has demonstrated efficacy in treating gastrointestinal disorders, including splenasthenic diarrhea. Ulcerative colitis (UC), a chronic inflammatory bowel disease, shares similarities with splenasthenic diarrhea. However, the pharmacological effects of C. heracleifolia on UC and the underlying mechanisms remain unexplored.
The present study investigates the therapeutic potential and mechanisms of C. heracleifolia in UC.
Initially, network pharmacology analysis, encompassing ingredient screening, target prediction, protein-protein interaction (PPI) network analysis, and enrichment analysis, was employed to predict the mechanisms of C. heracleifolia. The findings were further validated using transcriptomics and functional assays in a dextran sulfate sodium (DSS)-induced UC model. Additionally, bioactive compounds were identified through surface plasmon resonance (SPR) analysis, molecular docking, and cell-based assays.
A total of 52 ingredients of C. heracleifolia were screened, and 32 key targets were identified within a PPI network comprising 285 potential therapeutic targets. Enrichment analysis indicated that the anti-UC effects of C. heracleifolia are mediated through immune response modulation and the inhibition of inflammatory signaling pathways. In vivo experiments showed that C. heracleifolia mitigated histological damage in the colon, reduced the expression of phosphorylated Akt1, nuclear factor-kappa B (NF-κB) p65, and inhibitor of Kappa B kinase α/β (IKKα/β), suppressed the content of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and enhanced the expression of tight junction proteins. Moreover, cimigenoside, caffeic acid, and methyl caffeate were identified as the bioactive constituents responsible for the UC treatment effects of C. heracleifolia.
In summary, this study is the first to demonstrate that C. heracleifolia exerts therapeutic effects on UC by enhancing the intestinal mucosal barrier and inhibiting the phosphatidylinositol 3-kinase (PI3K)/AKT/NF-κB signaling pathway. These findings offer valuable insights into the clinical application of C. heracleifolia for UC management.
[Display omitted]
•The potential mechanism of Cimicifuga heracleifolia Kom. in ulcerative colitis was firstly reported by network pharmacology-based approach.•Cimicifuga heracleifolia Kom. repaired intestinal barrier.•Cimicifuga heracleifolia Kom. reduced DSS-induced colon inflammation.•Cimicifuga heracleifolia Kom. improved ulcerative colitis by regulating PI3K/AKT/NF-κB signaling pathway.</description><identifier>ISSN: 0378-8741</identifier><identifier>ISSN: 1872-7573</identifier><identifier>EISSN: 1872-7573</identifier><identifier>DOI: 10.1016/j.jep.2024.118892</identifier><identifier>PMID: 39395768</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Animals ; Anti-inflammation ; Anti-Inflammatory Agents - isolation & purification ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Cimicifuga - chemistry ; Cimicifuga heracleifolia Kom ; Colitis, Ulcerative - chemically induced ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - metabolism ; Colitis, Ulcerative - pathology ; Dextran Sulfate ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Molecular Docking Simulation ; Network Pharmacology ; NF-kappa B - metabolism ; Phosphatidylinositol 3-Kinase - metabolism ; Phosphatidylinositol 3-Kinases - metabolism ; Plant Extracts - pharmacology ; Plant Extracts - therapeutic use ; Protein Interaction Maps ; Proto-Oncogene Proteins c-akt - metabolism ; Signal Transduction - drug effects ; Ulcerative colitis</subject><ispartof>Journal of ethnopharmacology, 2025-01, Vol.337 (Pt 3), p.118892, Article 118892</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c235t-71bd3b15a3d2a41ed080b6be00b62788bd52259f927622f94a16ac78165bcec33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jep.2024.118892$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39395768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Xue-Yi</creatorcontrib><creatorcontrib>Dong, Qin-Wei</creatorcontrib><creatorcontrib>Zhang, Yong-Bo</creatorcontrib><creatorcontrib>Li, Jia-Xin</creatorcontrib><creatorcontrib>Zhang, Mei-Qing</creatorcontrib><creatorcontrib>Zhang, De-Qin</creatorcontrib><creatorcontrib>Cui, Yuan-Lu</creatorcontrib><title>Cimicifuga heracleifolia kom. Attenuates ulcerative colitis through the PI3K/AKT/NF-κB signaling pathway</title><title>Journal of ethnopharmacology</title><addtitle>J Ethnopharmacol</addtitle><description>Cimicifuga heracleifolia Kom. (C. heracleifolia) has demonstrated efficacy in treating gastrointestinal disorders, including splenasthenic diarrhea. Ulcerative colitis (UC), a chronic inflammatory bowel disease, shares similarities with splenasthenic diarrhea. However, the pharmacological effects of C. heracleifolia on UC and the underlying mechanisms remain unexplored.
The present study investigates the therapeutic potential and mechanisms of C. heracleifolia in UC.
Initially, network pharmacology analysis, encompassing ingredient screening, target prediction, protein-protein interaction (PPI) network analysis, and enrichment analysis, was employed to predict the mechanisms of C. heracleifolia. The findings were further validated using transcriptomics and functional assays in a dextran sulfate sodium (DSS)-induced UC model. Additionally, bioactive compounds were identified through surface plasmon resonance (SPR) analysis, molecular docking, and cell-based assays.
A total of 52 ingredients of C. heracleifolia were screened, and 32 key targets were identified within a PPI network comprising 285 potential therapeutic targets. Enrichment analysis indicated that the anti-UC effects of C. heracleifolia are mediated through immune response modulation and the inhibition of inflammatory signaling pathways. In vivo experiments showed that C. heracleifolia mitigated histological damage in the colon, reduced the expression of phosphorylated Akt1, nuclear factor-kappa B (NF-κB) p65, and inhibitor of Kappa B kinase α/β (IKKα/β), suppressed the content of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and enhanced the expression of tight junction proteins. Moreover, cimigenoside, caffeic acid, and methyl caffeate were identified as the bioactive constituents responsible for the UC treatment effects of C. heracleifolia.
In summary, this study is the first to demonstrate that C. heracleifolia exerts therapeutic effects on UC by enhancing the intestinal mucosal barrier and inhibiting the phosphatidylinositol 3-kinase (PI3K)/AKT/NF-κB signaling pathway. These findings offer valuable insights into the clinical application of C. heracleifolia for UC management.
[Display omitted]
•The potential mechanism of Cimicifuga heracleifolia Kom. in ulcerative colitis was firstly reported by network pharmacology-based approach.•Cimicifuga heracleifolia Kom. repaired intestinal barrier.•Cimicifuga heracleifolia Kom. reduced DSS-induced colon inflammation.•Cimicifuga heracleifolia Kom. improved ulcerative colitis by regulating PI3K/AKT/NF-κB signaling pathway.</description><subject>Animals</subject><subject>Anti-inflammation</subject><subject>Anti-Inflammatory Agents - isolation & purification</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Cimicifuga - chemistry</subject><subject>Cimicifuga heracleifolia Kom</subject><subject>Colitis, Ulcerative - chemically induced</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Colitis, Ulcerative - metabolism</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Dextran Sulfate</subject><subject>Humans</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Molecular Docking Simulation</subject><subject>Network Pharmacology</subject><subject>NF-kappa B - metabolism</subject><subject>Phosphatidylinositol 3-Kinase - metabolism</subject><subject>Phosphatidylinositol 3-Kinases - metabolism</subject><subject>Plant Extracts - pharmacology</subject><subject>Plant Extracts - therapeutic use</subject><subject>Protein Interaction Maps</subject><subject>Proto-Oncogene Proteins c-akt - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Ulcerative colitis</subject><issn>0378-8741</issn><issn>1872-7573</issn><issn>1872-7573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9u1DAQhy0EotvCA_RS-cglWY-dxI56WlYtVK2AQzlbjjPZ9TZ_FtvZqq_GQ_BMdbWFI5eZw3y_nzQfIefAcmBQLXf5Dvc5Z7zIAZSq-RuyACV5Jksp3pIFE1JlShZwQk5D2DHGJBTsPTkRtahLWakFcWs3OOu6eWPoFr2xPbpu6p2hD9OQ01WMOM4mYqBzb9M9ugNSm4DoAo1bP82bbdpIf9yI2-Xq9n757Tr78_szDW4zmt6NG7o3cftonj6Qd53pA3583Wfk5_XV_fprdvf9y816dZdZLsqYSWha0UBpRMtNAdgyxZqqQZYml0o1bcl5WXc1lxXnXV0YqIyVCqqysWiFOCOfjr17P_2aMUQ9uGCx782I0xy0ACjrqgZZJBSOqPVTCB47vfduMP5JA9MvhvVOJ8P6xbA-Gk6Zi9f6uRmw_Zf4qzQBl0cA05MHh14H63C02DqPNup2cv-pfwYfQIxc</recordid><startdate>20250130</startdate><enddate>20250130</enddate><creator>Wu, Xue-Yi</creator><creator>Dong, Qin-Wei</creator><creator>Zhang, Yong-Bo</creator><creator>Li, Jia-Xin</creator><creator>Zhang, Mei-Qing</creator><creator>Zhang, De-Qin</creator><creator>Cui, Yuan-Lu</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20250130</creationdate><title>Cimicifuga heracleifolia kom. Attenuates ulcerative colitis through the PI3K/AKT/NF-κB signaling pathway</title><author>Wu, Xue-Yi ; Dong, Qin-Wei ; Zhang, Yong-Bo ; Li, Jia-Xin ; Zhang, Mei-Qing ; Zhang, De-Qin ; Cui, Yuan-Lu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c235t-71bd3b15a3d2a41ed080b6be00b62788bd52259f927622f94a16ac78165bcec33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Animals</topic><topic>Anti-inflammation</topic><topic>Anti-Inflammatory Agents - isolation & purification</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Cimicifuga - chemistry</topic><topic>Cimicifuga heracleifolia Kom</topic><topic>Colitis, Ulcerative - chemically induced</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Colitis, Ulcerative - metabolism</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Dextran Sulfate</topic><topic>Humans</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Molecular Docking Simulation</topic><topic>Network Pharmacology</topic><topic>NF-kappa B - metabolism</topic><topic>Phosphatidylinositol 3-Kinase - metabolism</topic><topic>Phosphatidylinositol 3-Kinases - metabolism</topic><topic>Plant Extracts - pharmacology</topic><topic>Plant Extracts - therapeutic use</topic><topic>Protein Interaction Maps</topic><topic>Proto-Oncogene Proteins c-akt - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Xue-Yi</creatorcontrib><creatorcontrib>Dong, Qin-Wei</creatorcontrib><creatorcontrib>Zhang, Yong-Bo</creatorcontrib><creatorcontrib>Li, Jia-Xin</creatorcontrib><creatorcontrib>Zhang, Mei-Qing</creatorcontrib><creatorcontrib>Zhang, De-Qin</creatorcontrib><creatorcontrib>Cui, Yuan-Lu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ethnopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Xue-Yi</au><au>Dong, Qin-Wei</au><au>Zhang, Yong-Bo</au><au>Li, Jia-Xin</au><au>Zhang, Mei-Qing</au><au>Zhang, De-Qin</au><au>Cui, Yuan-Lu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cimicifuga heracleifolia kom. Attenuates ulcerative colitis through the PI3K/AKT/NF-κB signaling pathway</atitle><jtitle>Journal of ethnopharmacology</jtitle><addtitle>J Ethnopharmacol</addtitle><date>2025-01-30</date><risdate>2025</risdate><volume>337</volume><issue>Pt 3</issue><spage>118892</spage><pages>118892-</pages><artnum>118892</artnum><issn>0378-8741</issn><issn>1872-7573</issn><eissn>1872-7573</eissn><abstract>Cimicifuga heracleifolia Kom. (C. heracleifolia) has demonstrated efficacy in treating gastrointestinal disorders, including splenasthenic diarrhea. Ulcerative colitis (UC), a chronic inflammatory bowel disease, shares similarities with splenasthenic diarrhea. However, the pharmacological effects of C. heracleifolia on UC and the underlying mechanisms remain unexplored.
The present study investigates the therapeutic potential and mechanisms of C. heracleifolia in UC.
Initially, network pharmacology analysis, encompassing ingredient screening, target prediction, protein-protein interaction (PPI) network analysis, and enrichment analysis, was employed to predict the mechanisms of C. heracleifolia. The findings were further validated using transcriptomics and functional assays in a dextran sulfate sodium (DSS)-induced UC model. Additionally, bioactive compounds were identified through surface plasmon resonance (SPR) analysis, molecular docking, and cell-based assays.
A total of 52 ingredients of C. heracleifolia were screened, and 32 key targets were identified within a PPI network comprising 285 potential therapeutic targets. Enrichment analysis indicated that the anti-UC effects of C. heracleifolia are mediated through immune response modulation and the inhibition of inflammatory signaling pathways. In vivo experiments showed that C. heracleifolia mitigated histological damage in the colon, reduced the expression of phosphorylated Akt1, nuclear factor-kappa B (NF-κB) p65, and inhibitor of Kappa B kinase α/β (IKKα/β), suppressed the content of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and enhanced the expression of tight junction proteins. Moreover, cimigenoside, caffeic acid, and methyl caffeate were identified as the bioactive constituents responsible for the UC treatment effects of C. heracleifolia.
In summary, this study is the first to demonstrate that C. heracleifolia exerts therapeutic effects on UC by enhancing the intestinal mucosal barrier and inhibiting the phosphatidylinositol 3-kinase (PI3K)/AKT/NF-κB signaling pathway. These findings offer valuable insights into the clinical application of C. heracleifolia for UC management.
[Display omitted]
•The potential mechanism of Cimicifuga heracleifolia Kom. in ulcerative colitis was firstly reported by network pharmacology-based approach.•Cimicifuga heracleifolia Kom. repaired intestinal barrier.•Cimicifuga heracleifolia Kom. reduced DSS-induced colon inflammation.•Cimicifuga heracleifolia Kom. improved ulcerative colitis by regulating PI3K/AKT/NF-κB signaling pathway.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>39395768</pmid><doi>10.1016/j.jep.2024.118892</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-8741 |
| ispartof | Journal of ethnopharmacology, 2025-01, Vol.337 (Pt 3), p.118892, Article 118892 |
| issn | 0378-8741 1872-7573 1872-7573 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3115969174 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Anti-inflammation Anti-Inflammatory Agents - isolation & purification Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Cimicifuga - chemistry Cimicifuga heracleifolia Kom Colitis, Ulcerative - chemically induced Colitis, Ulcerative - drug therapy Colitis, Ulcerative - metabolism Colitis, Ulcerative - pathology Dextran Sulfate Humans Male Mice Mice, Inbred C57BL Molecular Docking Simulation Network Pharmacology NF-kappa B - metabolism Phosphatidylinositol 3-Kinase - metabolism Phosphatidylinositol 3-Kinases - metabolism Plant Extracts - pharmacology Plant Extracts - therapeutic use Protein Interaction Maps Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects Ulcerative colitis |
| title | Cimicifuga heracleifolia kom. Attenuates ulcerative colitis through the PI3K/AKT/NF-κB signaling pathway |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T14%3A52%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cimicifuga%20heracleifolia%20kom.%20Attenuates%20ulcerative%20colitis%20through%20the%20PI3K/AKT/NF-%CE%BAB%20signaling%20pathway&rft.jtitle=Journal%20of%20ethnopharmacology&rft.au=Wu,%20Xue-Yi&rft.date=2025-01-30&rft.volume=337&rft.issue=Pt%203&rft.spage=118892&rft.pages=118892-&rft.artnum=118892&rft.issn=0378-8741&rft.eissn=1872-7573&rft_id=info:doi/10.1016/j.jep.2024.118892&rft_dat=%3Cproquest_cross%3E3115969174%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3115969174&rft_id=info:pmid/39395768&rft_els_id=S0378874124011917&rfr_iscdi=true |